1. Recognition, pathogenesis, and treatment of different stages of nephropathy in the type 2 diabetes mellitus patient;Bakris;Mayo Clin Proc,2011
2. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.;Scheen;Diabetes Obes Metab,2010
3. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.;Blech;Drug Metab Dispos,2010
4. Food and Drug Administration. Guidance for Industry. Pharmacokinetics in Patients with Impaired Renal Function-Study Design, Data Analysis, and Impact on Dosing and Labeling. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf
5. Committee for Medicinal Products for Human Use. Note for Guidance on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Renal Function. European Medicines Agency, 2004. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003123.pdf